Kamel Walaa A, Kamel Mohmed I, Alhasawi Almunther, Elmasry Sameh, AlHamdan Fajer, Al-Hashel Jasem Y
Neurology Department, Faculty of Medicine, Beni-Suef University, Beni-Suef, Egypt.
Neurology Department, Ibn-Sina Hospital, Kuwait City, Kuwait.
Front Neurol. 2021 Oct 7;12:704186. doi: 10.3389/fneur.2021.704186. eCollection 2021.
Amantadine has been proposed to inhibit E-channel conductance in reconstituted lipid bilayers of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We aimed to study whether patients on amantadine have altered risks of contracting COVID-19 infection. We conducted a hospital-based, observational, retrospective cohort study using data for patients on amantadine supported by data given by the patients through an online questionnaire. We included registered amantadine users in our hospital for 6 months or more on March 1, 2020, and non-amantadine users to act as the control group. We used forced entry, multiple logistic regression models to estimate adjusted ORs for amantadine adjusting for the confounders. Between September 1, 2019, and March 1, 2020, 212 patients with Parkinson's disease (PD) or multiple sclerosis (MS) received greater than one equal to two prescriptions of amantadine. We selected a random sample of diagnoses which matched 424 patients of non-amantadine users (1:2) as a control group (424 patients). Between March 1, 2020, and March 1, 2021, 256 patients responded to our online questionnaire, 87 patients were on amantadine (group I), and 169 patients were not (control group, group II). COVID-19 disease infection proved to be 5.7 and 11.8% in group I and II patients, respectively. Increased odds of COVID-19 in multivariable-adjusted models were associated with old age and history of contact with COVID cases. Amantadine was associated with a significantly reduced risk of COVID-19 disease infection (adjusted OR 0.256, 95% CI 0.074-0.888). Amantadine is associated with a reduced risk of COVID-19 infection after adjusting for a broad range of variables. History of contact with COVID cases and old age are risk factors for COVID-19 infection. Therefore, we recommended randomized clinical trials investigating amantadine use for the prevention of COVID-19.
金刚烷胺被认为可抑制严重急性呼吸综合征冠状病毒2（SARS-CoV-2）重组脂质双层中的E通道电导。我们旨在研究服用金刚烷胺的患者感染2019冠状病毒病（COVID-19）的风险是否有所改变。我们开展了一项基于医院的观察性回顾性队列研究，利用患者通过在线问卷提供的数据，研究服用金刚烷胺的患者情况。我们纳入了在2020年3月1日已在我院使用金刚烷胺6个月或更长时间的注册用户，并将未使用金刚烷胺的用户作为对照组。我们使用强制进入的多元逻辑回归模型来估计调整混杂因素后金刚烷胺的调整比值比（OR）。在2019年9月1日至2020年3月1日期间，212例帕金森病（PD）或多发性硬化症（MS）患者接受了大于等于两份金刚烷胺处方。我们随机抽取了与424例未使用金刚烷胺的患者（1:2）诊断匹配的样本作为对照组（424例患者）。在2020年3月1日至2021年3月1日期间，256例患者回复了我们的在线问卷，87例患者服用金刚烷胺（第一组），169例患者未服用（对照组，第二组）。COVID-19疾病感染在第一组和第二组患者中的发生率分别为5.7%和11.8%。多变量调整模型中COVID-19感染几率增加与老年和接触COVID病例史有关。金刚烷胺与COVID-19疾病感染风险显著降低相关（调整后的OR为0.256，95%可信区间为0.074-0.888）。在调整了一系列变量后，金刚烷胺与COVID-19感染风险降低相关。接触COVID病例史和老年是COVID-19感染的危险因素。因此，我们建议开展随机临床试验，研究使用金刚烷胺预防COVID-19的效果。
